3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
2
Small Cell Lung Carcinoma
1
Pathologic Complete Response
1
Neutropenia
1
Neoplasms
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Limited Stage Small Cell Lung Cancer
1
Hemangiosarcoma
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
Fulvestrant
63
Letrozole
53
Paclitaxel
50
Trastuzumab
42
pembrolizumab
40
ribociclib
38
Specimen Handling
37
palbociclib
36
Capecitabine
35
Carboplatin
33
Anastrozole
33
Tamoxifen
32
exemestane
29
pertuzumab
28
abemaciclib
28
Magnetic Resonance Spectroscopy
26
Cyclophosphamide
26
trastuzumab deruxtecan
25
Surveys and Questionnaires
22
Biopsy
19
olaparib
18
Standard of Care
18
Radiotherapy
18
Docetaxel
16
Blood Specimen Collection
16
elacestrant
14
Taxes
14
Mastectomy, Segmental
14
eribulin
13
Methods
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Breast Neoplasms
×
trilaciclib
×
90 days
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled